Merck (MRK) Stock Surges 8% on Strong Q1 Results and Improved 2026 Outlook

Key Highlights

• Merck KGaA reported Q1 net income of €669 million, declining 9.4% annually, yet delivered earnings per share of €2.11, surpassing the €1.99 consensus estimate.
• Quarterly revenue decreased 2.8% to €5.13 billion, narrowly exceeding analyst projections of €5.09 billion.
• Management upgraded its 2026 adjusted EBITDA forecast to a range of €5.7–€6.1 billion from the previous €5.5–€6.0 billion target.
• The Electronics segment delivered impressive performance, powered by robust demand for AI and advanced computing materials.
• Market entry for generic versions of multiple sclerosis treatment Mavenclad was delayed from March to May, providing additional revenue protection.

Merck KGaA delivered first-quarter results on Wednesday that surpassed analyst expectations despite a year-over-year profit decline, triggering an 8% share price surge to levels not seen in two months.

Merck & Co., Inc., MRK

The German pharmaceutical and chemicals giant reported quarterly net income of €669 million, representing a 9.4% decrease from the prior-year period, translating to €2.11 per share—comfortably above the €1.99 analyst consensus. Revenue totaled €5.13 billion, a 2.8% decline year-over-year, yet marginally exceeding the €5.09 billion estimate. Currency fluctuations weighed on top-line performance, though core business momentum proved more resilient than anticipated.

Investor enthusiasm was particularly driven by the company’s decision to increase its full-year 2026 financial projections.

Management now anticipates adjusted EBITDA in the €5.7 billion to €6.1 billion range for 2026, representing an upward revision from the previously communicated €5.5 billion to €6.0 billion guidance. Revenue expectations were established at €20.4 billion to €21.4 billion. The organic sales growth forecast was also improved to a range of 0%–3%, up from the prior -1% to 2% projection.

Electronics Division Drives Performance

The Electronics business unit emerged as the quarter’s top performer. Strong appetite for specialized materials utilized in cutting-edge semiconductor manufacturing—especially those supporting AI infrastructure and high-performance computing applications—fueled robust expansion.

While this momentum isn’t entirely novel for Merck, the ongoing AI-driven semiconductor boom continues to serve as a powerful growth catalyst for this segment.

Adjusted EBITDA for the first quarter reached €1.53 billion, representing a marginal 0.3% decline, while comfortably surpassing the €1.46 billion analyst consensus.

Life Science Segment Gains Breathing Room

The Life Science business unit also posted results that exceeded expectations. Currency-adjusted revenue climbed 8.3%, partially attributed to one customer establishing a new distribution facility and other clients building inventory buffers amid supply chain uncertainties related to the Iran conflict.

Merck had previously indicated that U.S. revenue from Mavenclad, its multiple sclerosis therapy, would face pressure beginning in March following the arrival of generic alternatives. That timeline has now shifted to May, providing the division with additional weeks of premium-priced sales.

To offset the eventual revenue erosion from Mavenclad, Merck is banking on specialized cancer treatments obtained through its $3.9 billion acquisition of SpringWorks Therapeutics completed last year.

Morgan Stanley analyst Thibault Boutherin indicated expectations for Merck to outperform following the quarterly beat, noting that full-year implications, including favorable foreign exchange impacts, point to approximately 1% upside versus consensus EBITDA and earnings per share projections.

These results also represent an encouraging start for newly appointed CEO Kai Beckmann, who was elevated from his previous role leading the electronics division earlier this month.

Organic earnings per share guidance was revised upward to €7.50–€8.20 from the prior €7.10–€8.00 range, while EBITDA organic growth expectations improved to -2% to 2% from the previous -4% to 1% outlook.

The post Merck (MRK) Stock Surges 8% on Strong Q1 Results and Improved 2026 Outlook appeared first on Blockonomi.